Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy.

Clin Infect Dis

Institute for Medical Microbiology, German National Consulting Laboratory for Toxoplasmosis, University Medical Center Goettingen, Germany.

Published: June 2012

Background: Treatment of Toxoplasma gondii infection acquired during pregnancy differs in many countries. In Germany, spiramycin is given until the 16th week of pregnancy, followed by at least 4 weeks of combination therapy with pyrimethamine, sulfadiazine, and folinic acid independent of the infection stage of the fetus. If infection of the fetus is confirmed by polymerase chain reaction or if fetal ultrasound indicates severe symptoms (hydrocephalus, ventricular dilation), treatment is continued until delivery with regular monitoring of pyrimethamine and sulfadiazine concentration in maternal blood and observation of possible adverse effects. In other European countries, such as France, only spiramycin is given unless infection of the fetus is proven.

Methods: To evaluate the effectiveness of the German treatment scheme, a retrospective analysis of 685 women who showed a serological constellation consistent with primary infection in pregnancy and their children was performed.

Results: We found an increased transmission rate to the fetus with increased time in gestation and a decreased risk of clinical manifestations. In comparison with studies performed in other countries, the overall transmission rate (4.8%) and the rate of clinical manifestations in newborns (1.6%) were lower.

Conclusions: Use of spiramycin from time of diagnosis of acute acquisition of infection by the pregnant woman until week 16, followed by pyrimethamine, sulfadiazine, and folinic acid for at least 4 weeks in combination with a standardized follow-up program is efficient in reducing transplacental transmission of the parasite and the burden of disease in the newborn.

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/cis234DOI Listing

Publication Analysis

Top Keywords

pyrimethamine sulfadiazine
12
toxoplasma gondii
8
gondii infection
8
infection pregnancy
8
weeks combination
8
sulfadiazine folinic
8
folinic acid
8
infection fetus
8
transmission rate
8
clinical manifestations
8

Similar Publications

Toxoplasmosis induced by Toxoplasma gondii is a well-known health threat, that prompts fatal encephalitis increased with immunocompromised patients, in addition, it can cause chorioretinitis, microcephaly, stillbirth in the fetus and even led to death. Standard therapy uses sulfadiazine and pyrimethamine drugs revealed beneficial results during the acute stage, however, it has severe side effects. UPLC-ESI-MS/MS used to explore C.

View Article and Find Full Text PDF

Glabridin exhibits potent inhibitory effects against Toxoplasma gondii in vitro and in vivo.

Parasit Vectors

December 2024

Laboratory of Parasitic Diseases, College of Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi Province, 030801, People's Republic of China.

Article Synopsis
  • Toxoplasma gondii is a common parasite in warm-blooded animals and humans, with current treatments like pyrimethamine and sulfadiazine having significant limitations, prompting a search for safer, more effective options.
  • This study focused on glabridin, a natural compound from a medicinal plant, finding it to be low in toxicity while effectively inhibiting T. gondii growth and altering its structure.
  • The results showed that glabridin improved survival rates in infected mice and affected T. gondii's metabolism, suggesting a promising new treatment avenue for this parasite.
View Article and Find Full Text PDF

Background: Some regions of Spain are withdrawing their pregnancy screening program for congenital toxoplasmosis (CT). The Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) was created to describe the current status of CT in Spain. The aims of this study were to describe the epidemiological and clinical characteristics of CT and to evaluate the effect of prenatal treatment on clinical outcomes to inform decision-making policies.

View Article and Find Full Text PDF

Evaluation of nitazoxanide in the treatment of experimental murine neurotoxoplasmosis.

Rev Inst Med Trop Sao Paulo

October 2024

Universidade Federal de Jataí, Instituto de Ciências da Saúde, Programa de Pós-Graduação em Ciências Aplicadas à Saúde, Jataí, Goiás, Brazil.

Article Synopsis
  • Toxoplasmosis is a common zoonotic disease that poses serious global health risks, particularly neurotoxoplasmosis, which has a high mortality rate.
  • This study tested the effectiveness of nitazoxanide on mice infected with neurotoxoplasmosis, comparing it to the standard treatment of pyrimethamine plus sulfadiazine.
  • Results showed that while nitazoxanide reduced parasitic load and had similar toxicity to standard treatment, it was less effective overall, making pyrimethamine and sulfadiazine the preferred option for treating this condition.
View Article and Find Full Text PDF
Article Synopsis
  • Toxoplasmosis is a prevalent parasite globally, and the study aims to find new, safer treatments for pregnant women and infants using nanoemulsion miltefosine (NEM).
  • NEM was formulated using triacetin, Tween 80, and ethanol, and when tested on mice and rats, it showed varying effectiveness against acute and chronic toxoplasmosis compared to other treatments like sulfadiazine (SDZ) and pyrimethamine (PYR).
  • The findings suggest that NEM effectively penetrates the blood-brain barrier, significantly reducing the number and size of tissue cysts in chronic toxoplasmosis, positioning it as a hopeful new therapeutic option.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!